— Frequently Asked Questions

Answers to Your Regulatory Questions

Answers to the questions executive teams most often ask when regulatory, clinical, or quality risk begins to affect approval timelines, evidence strategy, inspection readiness, or commercial confidence.

A confidential discussion to assess your situation and determine whether SHOTUNE is the right fit.

18+

Years of Global MedTech Leadership

70+

Successful CE Mark
Approvals

I–III

Device Classes
Covered

100%

Founder-Led
Engagement

Filter by topic

We have a stalled FDA or CE Mark submission. Can SHOTUNE step in midstream?

Yes. SHOTUNE is often engaged midstream when submissions stall because of evidence gaps, weak regulator-facing logic, or misalignment across clinical, regulatory, and quality functions. We assess the root cause, clarify options, and help leadership determine the fastest defensible path to restore momentum.

Our Notified Body is pushing back on our CER, PMCF, or technical documentation. How do you handle this?

Notified Body pushback is rarely about documents alone. It usually signals concern about evidence defensibility, benefit-risk logic, or strategic coherence. SHOTUNE helps teams realign the regulatory, clinical, and risk narrative, close critical gaps, and reduce iterative review cycles.

Do you engage directly with regulators and Notified Bodies?

Yes. SHOTUNE supports structured FDA and Notified Body interactions, including pre-submission strategy, question responses, inspection readiness, and escalation planning. The focus is not only compliance, but regulator-aligned communication and decision discipline.

How is SHOTUNE different from large consulting firms or independent consultants?

SHOTUNE is founder-led, selectively scoped, and directly accountable. Clients do not receive delegated consulting or generic deliverables. They receive integrated clinical, regulatory, and quality judgment under one senior leader with enterprise MedTech experience.

What types of companies benefit most from working with SHOTUNE?

SHOTUNE is best suited to medical device companies operating in high-stakes regulatory environments—startups approaching major milestones, growth-stage companies entering new markets, established manufacturers facing complex lifecycle demands, and organizations preparing for diligence, remediation, or regulator scrutiny.

We are a growth-stage company, not a large manufacturer. Are we the right fit?

Potentially, yes. SHOTUNE is often most valuable when growth-stage companies are approaching consequential decisions and need senior judgment before risk becomes expensive. Fit depends less on company size than on the materiality of the regulatory, clinical, or quality decision.

Do you work on project-based, fractional, or escalation support engagements?

Yes. Engagements are selectively scoped based on the strategic need and may be structured as project-based support, fractional leadership, or escalation support during high-stakes approval, audit, or diligence periods.

How does SHOTUNE support diligence, transactions, or investor readiness?

SHOTUNE helps leadership identify and address regulatory, clinical, and quality exposures that may affect diligence outcomes, valuation confidence, or commercial narratives. The goal is to improve clarity, defensibility, and executive readiness before scrutiny intensifies.

Our quality system passes audits, but leadership still has concerns. Can SHOTUNE help?

Yes. Passing audits does not always equate to regulator confidence or enterprise resilience. SHOTUNE evaluates whether system outputs truly support regulatory and clinical expectations, identifies structural weaknesses, and strengthens governance where risk may still exist.

How do you integrate clinical evidence, regulatory strategy, and quality governance?

Under FDA and EU MDR, these functions are inseparable. SHOTUNE aligns evidence strategy, regulatory logic, quality system outputs, and risk management so that approvals, inspections, and post-market obligations are supported by a coherent decision framework.

We have a stalled FDA or CE Mark submission. Can SHOTUNE step in midstream?

Yes. For startups, that often means correcting a pathway or evidence problem before valuable time and capital are lost. For growth-stage and larger organizations, it often means stabilizing a submission that is already drawing repeated objections, internal rework, or executive concern.

Our pathway, classification, or predicate is still unclear. Can SHOTUNE help us decide before we lose time?

Yes. Early regulatory ambiguity is expensive for smaller companies because it delays development decisions and investor milestones. For scaling and established manufacturers, it can create downstream claims, evidence, and portfolio planning problems that are much harder to unwind later.

FDA or our Notified Body feedback keeps escalating unpredictably. How does SHOTUNE help?

Escalating feedback usually means the issue is not just the response letter. It is a deeper misalignment between pathway, evidence, claims, and risk logic. SHOTUNE helps leadership reframe the strategy, strengthen the regulator-facing narrative, and reduce further review-cycle erosion.

Do you engage directly with FDA and Notified Bodies?

Yes. SHOTUNE supports pre-submission strategy, formal interactions, responses to questions, and escalation planning. For lean teams, that brings needed senior leadership into critical moments. For larger teams, it provides higher-level strategic control when internal bandwidth or alignment is strained.

How is SHOTUNE different from traditional regulatory consulting firms?

SHOTUNE is founder-led, judgment-driven, and directly accountable. That matters whether you are a startup that cannot afford avoidable missteps, a scaling company trying to commercialize with confidence, or a larger manufacturer that needs senior regulatory leadership rather than more document throughput.

Can SHOTUNE help if prior advice has already led to rework or lost momentum?

Yes. That is often when SHOTUNE is engaged. We assess what is salvageable, identify where the strategy broke down, and help your team move forward with clearer decisions and stronger regulator alignment.

How does SHOTUNE design clinical strategy to meet FDA and EU MDR expectations?

SHOTUNE designs clinical strategy around regulator decisions, not data accumulation. For startups, that helps prevent overbuilding or underbuilding the evidence plan. For more mature organizations, it helps ensure evidence remains aligned to claims, benefit-risk, and lifecycle obligations as the product and markets evolve.

Our existing data does not clearly support our claims. Can SHOTUNE help?

Yes. For smaller companies, that may mean identifying the minimum defensible path forward before capital is consumed on the wrong work. For larger organizations, it often means determining whether the issue is a true evidence gap, a claims problem, or a broader strategy misalignment.

Can you support clinical programs that are already underway or poorly aligned?

Yes. SHOTUNE is often brought in when an active or legacy program no longer supports current regulatory expectations or commercialization goals. We reassess what the data can credibly support, what needs to change, and how to move forward without unnecessary additional burden.

Our Notified Body is pushing back on our CER, PMCF, or technical documentation. How do you handle this?

Notified Body pushback usually reflects concern with the underlying evidence logic, not just the wording. SHOTUNE helps realign CER, PMCF, claims, and benefit-risk rationale so the full story is more coherent, defensible, and commercially realistic.

Do you support PMS and PMCF strategy?

Yes. For growth-stage and larger manufacturers especially, PMS and PMCF should not be treated as disconnected compliance activity. SHOTUNE helps design proportionate post-market strategies that meet expectations, preserve resources, and support lifecycle decision-making across markets.

How do you integrate clinical evidence with quality and risk management?

Clinical evidence is not credible in isolation. SHOTUNE aligns evidence, claims, risk management, and post-market processes so your organization can defend one integrated position across regulatory, clinical, and quality functions.

Our quality system passes audits, but regulators still raise concerns. Can SHOTUNE help?

Yes. Passing audits does not always mean the system is strategically strong. For smaller companies, the issue is often that the QMS is technically present but not robust enough for growth. For larger organizations, it is often that outputs across quality, regulatory, and clinical functions are not fully aligned under scrutiny.

How does SHOTUNE build quality systems for scaling and global expansion?

SHOTUNE helps build quality systems that can absorb product growth, design changes, market expansion, and post-market obligations without repeated remediation. That is particularly important for growth-stage companies moving from basic compliance toward durable operating infrastructure.

Can SHOTUNE help us prepare for FDA inspections, Notified Body audits, or diligence review?

Yes. SHOTUNE helps organizations identify weak points before they become findings, strengthen inspection readiness, and improve the cross-functional quality posture that regulators, auditors, and investors actually evaluate.

How do you integrate risk management with clinical evidence and regulatory strategy?

Risk management should actively shape claims, evidence, PMS, and submission logic. SHOTUNE helps ensure risk files are not treated as standalone documentation, but as part of a connected system that supports defensible decisions across the product lifecycle.

Can SHOTUNE help when CAPAs, audit findings, or post-market issues keep recurring?

Yes. Recurring issues usually point to a structural control problem rather than an isolated event. SHOTUNE helps leadership identify the deeper pattern, strengthen governance, and reduce the cycle of repeated remediation and operational drag.

What does SHOTUNE do differently from traditional quality consultants?

SHOTUNE approaches quality as enterprise control architecture, not just SOP maintenance. That matters for startups trying to build correctly, growth-stage organizations scaling under pressure, and larger manufacturers that need senior judgment during audit strain, remediation, or diligence.

Need Clarity on Whether Your Situation Requires Escalation?

Bring your situation. You will leave with clearer options and a better sense of whether SHOTUNE is the right fit.